Digoxin
Digoxin is used for treating heart failure and slowing the heart rate in patients with chronic atrial fibrillation, a type of abnormal heart rhythm.
| Product dosage: 0.25mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.53 | $48.00 (0%) | đź›’ Add to cart |
| 120 | $0.49 | $64.00 $59.00 (8%) | đź›’ Add to cart |
| 180 | $0.46 | $96.00 $83.00 (14%) | đź›’ Add to cart |
| 270 | $0.43 | $144.00 $117.00 (19%) | đź›’ Add to cart |
| 360 | $0.42
Best per pill | $192.00 $152.00 (21%) | đź›’ Add to cart |
Synonyms | |||
Similar products
More info:
Actoplus Met: Dual-Action Control for Type 2 Diabetes
Actoplus Met combines two proven antihyperglycemic agents, pioglitazone and metformin, into a single tablet to provide comprehensive glycemic management for adults with type 2 diabetes mellitus. This fixed-dose combination therapy targets two key pathophysiological defects of the disease—insulin resistance and hepatic glucose overproduction—offering a synergistic approach to lower both fasting and postprandial blood glucose levels. By addressing multiple mechanisms simultaneously, it can simplify treatment regimens and improve adherence, which is critical for long-term metabolic control and reducing the risk of diabetes-related complications.
Glucophage: Advanced Metformin Therapy for Effective Blood Sugar Control
Glucophage, the pioneering brand of metformin hydrochloride, stands as a first-line pharmacological intervention in the management of type 2 diabetes mellitus. This biguanide-class medication operates by addressing core pathophysiological defects: reducing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. Its well-established efficacy, favorable safety profile, and extensive clinical history make it a cornerstone of modern diabetology. Prescribed by healthcare professionals worldwide, Glucophage represents a critical tool in achieving and maintaining glycemic targets, thereby reducing the risk of diabetes-related complications.
Glycomet SR: Advanced Sustained-Release Metformin for Type 2 Diabetes Management
Glycomet SR is a pharmaceutical formulation of metformin hydrochloride, designed with a sustained-release mechanism to optimize glycemic control in patients with type 2 diabetes mellitus. As a biguanide-class oral antihyperglycemic agent, it functions primarily by reducing hepatic glucose production and enhancing peripheral insulin sensitivity. This extended-release formulation allows for once-daily dosing, improving patient adherence while minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Clinical evidence supports its efficacy in lowering both fasting and postprandial blood glucose levels, with additional benefits on lipid metabolism and potential cardiovascular risk reduction.
Glyset: Advanced Glycemic Control for Type 2 Diabetes
Glyset (miglitol) is an alpha-glucosidase inhibitor specifically designed to manage blood glucose levels in adults with type 2 diabetes mellitus. By delaying the digestion of carbohydrates in the small intestine, it reduces the postprandial rise in blood glucose, offering a targeted mechanism complementary to diet and exercise. This oral antidiabetic agent is particularly effective in moderating glucose spikes after meals, providing a non-systemic approach to glycemic management. It is often prescribed as monotherapy or in combination with other glucose-lowering agents when additional control is necessary.
Januvia: Advanced DPP-4 Inhibitor for Effective Type 2 Diabetes Management
Januvia (sitagliptin) is an oral antihyperglycemic agent indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. As a selective dipeptidyl peptidase-4 (DPP-4) inhibitor, it works by enhancing the body’s own ability to lower elevated blood sugar levels through the incretin system. This medication is commonly used both as monotherapy and in combination with other antidiabetic agents, offering a targeted mechanism with a favorable tolerability profile for long-term diabetes management.
Metformin: The Cornerstone of Type 2 Diabetes Management
Metformin hydrochloride is a first-line, biguanide-class oral antihyperglycemic agent, widely recognized as the foundational pharmacological therapy for the management of type 2 diabetes mellitus (T2DM). Its primary mechanism of action involves decreasing hepatic glucose production (gluconeogenesis) and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike many other antidiabetic agents, metformin is not associated with weight gain and carries a low risk of hypoglycemia when used as monotherapy, making it a preferred initial choice for clinicians worldwide.
Onglyza: Advanced DPP-4 Inhibitor for Type 2 Diabetes Management
Onglyza (saxagliptin) is a prescription medication designed to improve glycemic control in adults with type 2 diabetes mellitus. As a dipeptidyl peptidase-4 (DPP-4) inhibitor, it works by enhancing the body’s natural ability to lower blood sugar when it is elevated. This medication is typically used in combination with diet and exercise, and may be prescribed alongside other antidiabetic agents such as metformin, sulfonylureas, or thiazolidinediones. Onglyza offers a targeted mechanism of action that supports sustained glucose management without causing weight gain in most patients.
Precose: Control Post-Meal Blood Sugar with Alpha-Glucosidase Inhibition
Precose (acarbose) is an oral alpha-glucosidase inhibitor medication designed specifically for the management of type 2 diabetes mellitus. It functions by delaying the digestion of complex carbohydrates and disaccharides in the small intestine, thereby reducing the postprandial rise in blood glucose. This mechanism offers a targeted approach to glycemic control, particularly after meals, and is often used as monotherapy or in combination with other antidiabetic agents like sulfonylureas, metformin, or insulin.
Tizacare: Advanced Topical Analgesic for Targeted Pain Relief
Tizacare represents a significant advancement in topical analgesic therapy, formulated for healthcare professionals seeking a reliable, fast-acting solution for musculoskeletal pain management. This prescription-strength medication combines a well-established active pharmaceutical ingredient with a sophisticated delivery system designed to maximize therapeutic effect while minimizing systemic exposure. Its targeted mechanism of action makes it an indispensable tool in both acute injury protocols and chronic pain management strategies, offering patients substantial relief without the gastrointestinal risks associated with oral NSAIDs.